VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?

(2017) Christine Böger et al.   OncoImmunology

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

(2016) Y. Kong et al.   CLINICAL CANCER RESEARCH

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia

(2015) Hui Sun et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

(2015) Frauke M. Schnorfeil et al.   Journal of Hematology & Oncology

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses

(2015) Jun Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation

(2015) Y Kong et al.   Blood Cancer Journal

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

(2015) Isabelle Le Mercier et al.   Frontiers in Immunology

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity

(2014) Dallas B. Flies et al.   JOURNAL OF CLINICAL INVESTIGATION

CD14+HLA-DRlow/− expression: A novel prognostic factor in chronic lymphocytic leukemia

(2014) JINLIN LIU et al.   Oncology Letters

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis

(2013) Hiroshi Katoh et al.   CANCER CELL

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells

(2011) B. Hoechst et al.   BLOOD

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation

(2011) W. J. Norde et al.   CANCER RESEARCH

Myeloid derived suppressor cells in human diseases

(2011) Tim F. Greten et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

(2011) D. B. Flies et al.   JOURNAL OF IMMUNOLOGY

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function

(2010) Moshe Elkabets et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

(2009) L. Zhang et al.   BLOOD

Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer

(2009) P.-Y. Pan et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

(2009) M. K. Srivastava et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells

(2009) E. M. Hanson et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells

(2008) P. Serafini et al.   CANCER RESEARCH